It is widely recognized in the field of synthetic lethality that molecularly targeted therapies such as PARP inhibitors possess the potential to greatly extend the progression-free and overall survival rates for individuals with BRCA1- or BRCA2-mutant ovarian cancer [29–31]. This evidence concerns the gene BRCA2 and ovarian carcinoma.